Clinical Trial: NCT04751929
Abemaciclib With or Without Atezolizumab for mCRPC
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-06-17 |
Study Overview
Brief Summary
This trial is testing whether a molecularly targeted chemotherapy drug called abemaciclib and an immunotherapy drug called atezolizumab, alone or in combination, are effective in shrinking or preventing the growth of metastatic prostate cancer. The trial is also testing the safety of the combination of abemaciclib with atezolizumab.
Official Title
A Phase II Multi-Center Trial of Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Intervention / Treatment
- Drug: Abemaciclib
- Drug: Atezolizumab
Other Study ID Numbers
- 20-701
Start Date (Actual)
2021-08-20
Primary Completion Date (Actual)
2024-06-17
Study Completion Date (Actual)
2025-11-06
Enrollment (Actual)
19
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-06-17 |
Study Overview
Brief Summary
This trial is testing whether a molecularly targeted chemotherapy drug called abemaciclib and an immunotherapy drug called atezolizumab, alone or in combination, are effective in shrinking or preventing the growth of metastatic prostate cancer. The trial is also testing the safety of the combination of abemaciclib with atezolizumab.
Official Title
A Phase II Multi-Center Trial of Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Intervention / Treatment
- Drug: Abemaciclib
- Drug: Atezolizumab
Other Study ID Numbers
- 20-701
Start Date (Actual)
2021-08-20
Primary Completion Date (Actual)
2024-06-17
Study Completion Date (Actual)
2025-11-06
Enrollment (Actual)
19
Study Type
Interventional
Phase
Phase 2